Anthony S.  Marucci net worth and biography

Anthony Marucci Biography and Net Worth

Mr. Marucci was appointed President and Chief Executive Officer of Celldex in September 2008 and as a director of Celldex in December 2008. Since May 2003, Mr. Marucci has held a number of roles with Celldex, including as a founder, Vice President, Chief Financial Officer, Treasurer and Secretary. In addition, he was Treasurer of Medarex, Inc. (now a part of Bristol-Myers Squibb Co.) from December 1998 to March 2004. Mr. Marucci held a series of senior financial positions at Medarex from December 1998 to May 2003. Since May 2021, Mr. Marucci serves as a member of the board of directors of Genenta Science S.p.A., a publicly held biopharmaceutical company. Mr. Marucci is a member of the Board of Trustees of BioNJ Inc. and also served as its Treasurer through 2010. Mr. Marucci is also a member of the Board of the College of Business and Public Management at Kean University. Mr. Marucci received his M.B.A. from Columbia University and his M.H.L. from Brown University.

What is Anthony S. Marucci's net worth?

The estimated net worth of Anthony S. Marucci is at least $802,860.12 as of November 11th, 2024. Mr. Marucci owns 40,284 shares of Celldex Therapeutics stock worth more than $802,860 as of March 30th. This net worth approximation does not reflect any other investments that Mr. Marucci may own. Additionally, Mr. Marucci receives a salary of $1,270,000.00 as CEO at Celldex Therapeutics. Learn More about Anthony S. Marucci's net worth.

How old is Anthony S. Marucci?

Mr. Marucci is currently 62 years old. There are 9 older executives and no younger executives at Celldex Therapeutics. Learn More on Anthony S. Marucci's age.

What is Anthony S. Marucci's salary?

As the CEO of Celldex Therapeutics, Inc., Mr. Marucci earns $1,270,000.00 per year. Learn More on Anthony S. Marucci's salary.

How do I contact Anthony S. Marucci?

The corporate mailing address for Mr. Marucci and other Celldex Therapeutics executives is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. Celldex Therapeutics can also be reached via phone at (908) 454-7120 and via email at ir@celldextherapeutics.com. Learn More on Anthony S. Marucci's contact information.

Has Anthony S. Marucci been buying or selling shares of Celldex Therapeutics?

Anthony S. Marucci has not been actively trading shares of Celldex Therapeutics over the course of the past ninety days. Most recently, on Monday, November 11th, Anthony S. Marucci bought 11,500 shares of Celldex Therapeutics stock. The stock was acquired at an average cost of $26.82 per share, with a total value of $308,430.00. Following the completion of the transaction, the chief executive officer now directly owns 40,284 shares of the company's stock, valued at $1,080,416.88. Learn More on Anthony S. Marucci's trading history.

Who are Celldex Therapeutics' active insiders?

Celldex Therapeutics' insider roster includes Sarah Cavanaugh (SVP), Elizabeth Crowley (VP), Margo Heath-Chiozzi (SVP), Freddy Jimenez (SVP), Samuel Martin (CFO), Anthonly Marucci (President & CEO), Anthony Marucci (CEO), Richard Wright (VP), and Diane Young (SVP). Learn More on Celldex Therapeutics' active insiders.

Are insiders buying or selling shares of Celldex Therapeutics?

In the last year, Celldex Therapeutics insiders bought shares 1 times. They purchased a total of 11,500 shares worth more than $308,430.00. In the last year, insiders at the biopharmaceutical company sold shares 8 times. They sold a total of 266,332 shares worth more than $9,155,821.33. The most recent insider tranaction occured on November, 11th when CEO Anthony S Marucci bought 11,500 shares worth more than $308,430.00. Insiders at Celldex Therapeutics own 3.8% of the company. Learn More about insider trades at Celldex Therapeutics.

Information on this page was last updated on 11/11/2024.

Anthony S. Marucci Insider Trading History at Celldex Therapeutics

See Full Table

Anthony S. Marucci Buying and Selling Activity at Celldex Therapeutics

This chart shows Anthony S Marucci's buying and selling at Celldex Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$200k$0$200kTotal Insider BuyingTotal Insider Selling

Celldex Therapeutics Company Overview

Celldex Therapeutics logo
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Read More

Today's Range

Now: $19.93
Low: $19.51
High: $20.19

50 Day Range

MA: $21.90
Low: $19.35
High: $25.51

2 Week Range

Now: $19.93
Low: $18.61
High: $47.00

Volume

673,963 shs

Average Volume

863,800 shs

Market Capitalization

$1.32 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.76